400 East Jamie Court,
South San Francisco
7 articles about Lycia Therapeutics
Lycia Therapeutics Founder Dr. Carolyn Bertozzi Awarded 2022 Nobel Prize in Chemistry
Lycia Therapeutics, Inc. announced that founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in Chemistry.
Lycia Therapeutics Strengthens Leadership Team with Appointment of Steve Staben, Ph.D. as Chief Scientific Officer
Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the recent appointment of Steve Staben, Ph.D., as Chief Scientific Officer.
Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.
Money on the Move: September 8 – 14
9/15/2021Ramping up after the Labor Day holiday, funds are flowing fast and free into these life science companies.
Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures
Lycia Therapeutics, Inc. today announced the completion of an oversubscribed $70 million Series B financing.
Lycia will be receiving a $35 million upfront payment from Lilly and is eligible for over $1.6 billion in potential milestone payments.
Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders
Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology.